What began as a moonshot became mundane. Mass Covid-19 testing overcame initial scepticism to become a mainstay of pandemic planning — and a money-spinner for test providers. Witness the record SFr1.9bn ($1.99bn) of test sales chalked up by Swiss pharma giant Roche in the first quarter, up 58 per cent on a year earlier. But it now appears the western market has peaked. Mass vaccination has radically reduced the severity of coronavirus — and the need to test for it.
最初的艰巨任务已变得平淡无奇。大规模新冠检测克服最初的怀疑，成为防疫规划的支柱，也成为检测试剂盒提供商的利润来源。不妨看一看瑞士制药巨头罗氏(Roche)第一季度创纪录的19亿瑞士法郎（合19.9亿美元）检测试剂盒销售额，同比增长58%。但现在看来，西方市场已经见顶。大规模疫苗接种从根本上降低了新冠症状的严重程度，以及对新冠感染进行检测的必要性。
您已阅读19%（643字），剩余81%（2802字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。